

University of Groningen

Pharmacoeconomics of cardiovascular disease prevention

Stevanovic, Jelena

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date:

2015

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Stevanovic, J. (2015). *Pharmacoeconomics of cardiovascular disease prevention*. [Thesis fully internal (DIV), University of Groningen]. University of Groningen.

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Pharmacoeconomics of cardiovascular disease prevention

Jelena Stevanović

Paranimfen: Milica Stanković-Brandl
Bianca Mulder

Cover design by Saša Dimitrijević

Layout by Henri van der Heiden

Printed by CPI Koninklijke Wöhrmann

ISBN (book) 978-90-367-8415-3

ISBN (electronic version) 978-90-367-8414-6

Printing of this thesis was financially supported by the University of Groningen, the Groningen Graduate School of Science, and the Graduate School for Health Research SHARE.

© 2015 Jelena Stevanović. No part of this thesis may be reproduced or transmitted in any form or by any means, electronical or mechanical, including photocopying, recording, or by any information storage or retrieval system, without written permission of the author. The copyright of previously printed chapters of this thesis remains with the publisher or journal.



rijksuniversiteit
 groningen

Pharmacoeconomics of cardiovascular disease prevention

Proefschrift

ter verkrijging van de graad van doctor aan de
 Rijksuniversiteit Groningen
 op gezag van de
 rector magnificus prof. dr. E. Sterken
 en volgens besluit van het College voor Promoties.

De openbare verdediging zal plaatsvinden op

dinsdag 22 december 2015 om 11.00 uur

door

Jelena Stevanović

geboren op 13 juli 1983
 te Niš, Servië

Promotor

Prof. dr. M.J. Postma

Copromotores

Dr. P. Pechlivanoglou

Dr. H.H. Le

Beoordelingscommissie

Prof. dr. B. Wilffert

Prof. dr. H.R. Büller

Prof. dr. G. Petrova

To my family

TABLE OF CONTENTS

Chapter 1: General Introduction	9
Part I: Simulating and synthesizing health and economic evidence in (primary) cardiovascular disease prevention.	21
Chapter 2: A systematic review on the application of cardiovascular risk prediction models in pharmacoeconomics, with a focus on primary prevention.	23
Chapter 3: Economic evaluation of primary prevention of cardiovascular diseases in mild hypertension. A scenario analysis for the Netherlands.	45
Annex: Incidence description and costs of acute heart failure in the Netherlands.	73
Chapter 4: Multivariate meta-analysis of preference-based quality of life values in coronary heart disease.	87
Part II: Pharmacoeconomic findings in secondary cardiovascular disease prevention; Focus on oral anticoagulation.	119
Chapter 5: Budget impact of increasing market-share of patient self-testing and patient self-management in anticoagulation.	121
Chapter 6: Economic evaluation of apixaban for the prevention of stroke in non-valvular atrial fibrillation in the Netherlands.	141
Chapter 7: Economic evaluation of dabigatran for the treatment and secondary prevention of venous thromboembolism.	165
Chapter 8: General Discussion	189
Summary	201
Samenvatting	203
List of publications	205
Acknowledgements	207
Research Institute of Science in Healthy Aging & health caRE (SHARE)	209
Curriculum Vitae	213

